Stocks
Integra LifeSciences Holdings Corporation Financial Statements (IART) |
||||||||||
| Integra LifeSciences Holdings Corporationsmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 21.02.2020 | 23.02.2021 | 24.02.2022 | 22.02.2023 | 31.12.2023 | 04.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 1 518 | 1 372 | 1 542 | 1 558 | 1 542 | 1 565 | |||
| Operating Income, bln rub | 179.0 | 151.4 | 197.2 | 238.9 | 111.5 | 86.9 | ||||
| EBITDA, bln rub | ? | 231.0 | 267.9 | 366.3 | 391.1 | 383.6 | 233.7 | |||
| Net profit, bln rub | ? | 50.2 | 133.9 | 169.1 | 180.6 | 67.7 | -6.54 | |||
| OCF, bln rub | ? | 373.7 | 203.8 | 312.4 | 264.5 | 140.0 | 137.4 | |||
| CAPEX, bln rub | ? | 134.5 | 63.9 | 48.1 | 47.1 | 66.9 | 99.4 | |||
| FCF, bln rub | ? | 239.2 | 139.9 | 264.3 | 217.4 | 73.1 | 38.0 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 794.2 | 699.7 | 747.4 | 731.4 | 836.4 | 786.6 | ||||
| Cost of production, bln rub | 564.7 | 520.8 | 597.8 | 587.4 | 653.2 | 691.4 | ||||
| R&D, bln rub | 79.6 | 77.4 | 93.1 | 101.2 | 174.6 | 103.7 | ||||
| Interest expenses, bln rub | 54.0 | 71.6 | 50.4 | 49.6 | 51.4 | 70.5 | ||||
| Assets, bln rub | 3 303 | 3 615 | 3 782 | 3 890 | 3 782 | 4 066 | ||||
| Net Assets, bln rub | ? | 1 417 | 1 515 | 1 685 | 1 804 | 1 588 | 1 522 | |||
| Debt, bln rub | 1 458 | 1 655 | 1 651 | 1 615 | 1 682 | 1 989 | ||||
| Cash, bln rub | 198.9 | 470.2 | 513.4 | 456.7 | 309.1 | 277.6 | ||||
| Net debt, bln rub | 1 259 | 1 185 | 1 138 | 1 159 | 1 373 | 1 712 | ||||
| Ordinary share price, rub | 58.3 | 64.9 | 67.0 | 56.1 | 43.6 | 37.8 | ||||
| Number of ordinary shares, mln | 85.6 | 84.7 | 84.7 | 83.0 | 78.2 | 76.4 | ||||
| Market cap, bln rub | 4 991 | 5 495 | 5 674 | 4 654 | 3 404 | 2 890 | ||||
| EV, bln rub | ? | 6 250 | 6 681 | 6 812 | 5 812 | 4 777 | 4 602 | |||
| Book value, bln rub | -569 | -407 | -474 | -361 | -535 | -804 | ||||
| EPS, rub | ? | 0.59 | 1.58 | 2.00 | 2.18 | 0.87 | -0.09 | |||
| FCF/share, rub | 2.79 | 1.65 | 3.12 | 2.62 | 0.94 | 0.50 | ||||
| BV/share, rub | -6.65 | -4.81 | -5.60 | -4.35 | -6.85 | -10.5 | ||||
| EBITDA margin, % | ? | 15.2% | 19.5% | 23.7% | 25.1% | 24.9% | 14.9% | |||
| Net margin, % | ? | 3.31% | 9.76% | 11.0% | 11.6% | 4.39% | -0.42% | |||
| FCF yield, % | ? | 4.79% | 2.55% | 4.66% | 4.67% | 2.15% | 1.32% | |||
| ROE, % | ? | 3.54% | 8.84% | 10.0% | 10.0% | 4.27% | -0.43% | |||
| ROA, % | ? | 1.52% | 3.70% | 4.47% | 4.64% | 1.79% | -0.16% | |||
| P/E | ? | 99.4 | 41.0 | 33.6 | 25.8 | 50.3 | -441.6 | |||
| P/FCF | 20.9 | 39.3 | 21.5 | 21.4 | 46.6 | 76.0 | ||||
| P/S | ? | 3.29 | 4.01 | 3.68 | 2.99 | 2.21 | 1.85 | |||
| P/BV | ? | -8.77 | -13.5 | -12.0 | -12.9 | -6.36 | -3.59 | |||
| EV/EBITDA | ? | 27.1 | 24.9 | 18.6 | 14.9 | 12.5 | 19.7 | |||
| Debt/EBITDA | 5.45 | 4.42 | 3.11 | 2.96 | 3.58 | 7.32 | ||||
| R&D/CAPEX, % | 59.1% | 121.1% | 193.5% | 214.9% | 261.1% | 104.4% | ||||
| CAPEX/Revenue, % | 8.87% | 4.66% | 3.12% | 3.02% | 4.34% | 6.35% | ||||
| Integra LifeSciences Holdings Corporation shareholders | ||||||||||
